Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14767MR)

This product GTTS-WQ14767MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Anaplastic large cell lymphoma (ALCL), Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14767MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5339MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ12330MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ11444MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ15903MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ1773MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ10836MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ4949MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ7110MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FE 999301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW